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Abstract: Choroidal neovascularization (CNV) secondary to age related macular degeneration 
is among the leading causes of legal blindness in developed countries. Photodynamic therapy 
(PDT) with verteporﬁ  n induces CNV closure causing little damage to healthy tissue, but the 
need to re-treat may lead to low ﬁ  nal visual acuity at an unacceptable cost. The association of 
intravitreous triamcinolone or antiangiogenic drugs with PDT has been used in order to reduce 
these limitations of the therapy. The combination of PDT and intravitreous triamcinolone, its 
complications and outcome at one and two-year follow-up are discussed.
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Introduction
Photodynamic therapy (PDT) with verteporﬁ  n signiﬁ  cantly reduces visual acuity 
(VA) loss in cases with subfoveal choroidal neovascularization (CNV) secondary to 
exudative age related macular degeneration (AMD) (Anon 1999; Bressler 2001), as 
well as the patient’s perception of scotoma (Schmidt-Erfurth et al 2004). However, 
several sessions are frequently needed to achieve complete closure of the lesions (3.4 
during the ﬁ  rst year, 2.2 during the second year and 1.3 during the third year) as was 
demonstrated by the results of randomized clinical trials (Anon 1999; Bressler 2001; 
Blumenkranz et al 2002) and the ﬁ  nal VA outcome is usually considered not good 
enough by the patient and the ophthalmologist.
It has been reported that CNV permeabilization and growth associated with 
exudative AMD make it necessary to perform repeated PDT sessions, reducing its 
cost-effectiveness (Sharma et al 2001; Meads and Hyde 2004; Brown et al 2005). 
Repeated PDT sessions may cause retinal damage and result in progressive thinning 
of the neurosensory retina (Reinke et al 1999; Peyman et al 2000), as well as closure 
of normal choroidal vessels (Michels and Schmidt-Erfurth 2003).
Combined therapies have been considered necessary to reduce the number of 
re-treatments and the progressive loss of VA. Intravitreal triamcinolone acetonide 
(TA) has been associated with PDT in order to join the short-term effect of PDT-
induced CNV closure (Meads and Hyde 2004) and the antiangiogenic and anti-
inﬂ  ammatory effects of TA (Spaide et al 2003). Intravitreal injection of TA is cheap 
and relatively safe, and TA appears to have a long half-life in the vitreous cavity 
(Tano et al 1980).
We have tried to determine the beneﬁ  ts of combining the short-term effect of PDT-
induced CNV closure (Miller et al 1995), with the antiangiogenic and anti-inﬂ  ammatory 
effects of TA (Tano et al 1980).Clinical Ophthalmology 2008:2(1) 72
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Material and methods
We analyzed the results of combined PDT and high dose TA 
in 30 eyes from 30 patients with AMD-associated CNV at 
the Alicante Institute of Ophthalmology at 12 and 24 month 
follow-up. The study was performed in accordance to the ethi-
cal standards of the 1964 Declaration of Helsinki, and data 
gathering was performed after obtaining written informed 
consent and approval of the Ethics Committee.
Patients older than 50 years of age with AMD-associated 
subfoveal CNVs veriﬁ  ed by ﬂ  uorescein angiography (FA) 
were included. CNVs occupied more than 50% of total 
lesion area; greatest linear dimension of the lesion was less 
than 5400 μm and baseline intraocular pressure (IOP) was 
under 21 mmHg.
Three groups of patients were considered. Group 1 com-
prised 15 naïve patients; Group 2 comprised 15 patients who 
had previously received PDT and showed persistent leakage 
on FA. We also considered 15 patients with AMD-associated 
subfoveal CNV who had been treated at our clinic with 
standard PDT as a Control Group. The three groups were 
not signiﬁ  cantly different for age, sex, best corrected visual 
acuity (BCVA), CNV size, and lesion type at baseline (Ruiz-
Moreno et al 2006b).
Conventional PDT as previously described (Anon 1999) 
was followed by an intravitreal injection of 19.4 ± 2.1 mg 
TA in 0.1 ml ﬁ  ve days later. This concentration of TA was 
obtained by allowing the 40 mg/ml triamcinolone suspen-
sion to precipitate within the injecting syringe (Ruiz-Moreno 
et al 2006a; Ruiz-Moreno et al 2006b; Ruiz-Moreno et al 
2007).
CNV leakage or growth demonstrated by FA was treated 
by additional PDT sessions not sooner than three months 
later. New TA injections were performed combined with 
PDT at six months intervals, when necessary.
Main outcome variables were BCVA at baseline and 
at month 12 and 24 (LogMAR), changes in visual acuity 
(Snellen lines), number of PDT sessions per patient, and 
appearance of adverse events.
Results
Demographics have been previously described (Ruiz-Moreno 
et al 2006b; Ruiz-Moreno et al 2007). Three patients in 
Group 2 had been treated by PDT once; six patients twice; 
four patients three times; one patient four times; and one 
patient six times (Ruiz-Moreno et al 2006b; Ruiz-Moreno 
et al 2007).
One patient (case 14) was excluded from Group 1 at 
month 3 due to migration of triamcinolone into the anterior 
chamber. One patient (case 2) in Group 2 lived far from the 
medical center and refused to return for follow-up visits.
Differences between baseline and 12 month BCVA for 
Groups 1 and 2 were not statistically signiﬁ  cant (p = 0.49 
and p = 0.10 respectively, Student t test for paired data). 
BCVA in the Control Group at month 12 was signiﬁ  cantly 
worse than in Groups 1 and 2 (p = 0.004, ANOVA). The 
changes in BCVA during the second year compared with 
baseline were not statistically signiﬁ  cant for Groups 1 and 2 
(p = 0.94 and p = 0.34 respectively, Student t test for paired 
data). BCVA in the Control Group was signiﬁ  cantly worse 
(p = 0.04, Student t test for paired data).
The presence of ﬂ  uorescein leakage and the need for PDT 
are shown in Table 1. The difference in the number of PDT 
sessions needed to stop FA leakage was statistically signiﬁ  -
cant at months 3, 6, 9, and 12 for Groups 1 and 2 compared 
to the historical Control Group. The average number of PDT 
sessions for the two-year period was 3.9 for the Control 
Group, 1.9 for Group 1 and 1.2 for Group 2. The average 
number of intravitreal TA injections was 1.5 in Group 1 and 
1.2 in Group 2. A second injection was needed in nine eyes 
during the 2 year follow-up.
Fifteen (54%) of 28 eyes from Groups 1 and 2 had high 
IOP needing medical therapy during the ﬁ  rst year. There were 
no cases of increased IOP in the Control Group. No new cases 
of IOP elevation appeared during the second year. Two eyes 
with high IOP needed a second intravitreal TA injection at 
month 15, which did not affect IOP.
IOP rose in ﬁ  ve cases one month after the injection, in 
four cases at month 3, in four cases at month 6, in one case at 
month 7, and in one case at month 9. One single topical drug 
controlled IOP in seven cases; two drugs were needed in seven 
cases, and one case underwent 180° diode laser cycloabla-
tion. The number of patients needing therapy to control IOP 
decreased progressively, and by the end of the second year 
Table 1 Number of PDT sessions performed
Month  Control   Group 1  Group 2  Statistical
 group      signiﬁ  cancea
3  14/15 (93%)  5/14 (36%)  1/15 (7%)  p   0.000
6  10/15 (67%)  3/14 (21%)  2/15 (13%)  p = 0.004
9  7/15 (47%)  1/14 (7%)  0/14 (0%)  p = 0.032
12  5/15 (33%)  0/14 (0%)  0/14 (0%)  p = 0.005
15  2/14 (14%)  2/14 (14%)  0/14 (0%)  NS
18  2/14 (14%)  1/14 (7%)  0/14 (0%)  NS
21  0/13 (0%)  0/13 (0%)  0/13 (0%)  NS
24  0/13 (0%)  0/13 (0%)  0/13 (0%)  NS
aChi square test.
Abbreviation: NS, not statistically signiﬁ  cant.Clinical Ophthalmology 2008:2(1) 73
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only 6 of 26 eyes (23%) still needed topical treatment to control 
IOP: two patients with two drugs, and four patients with one 
drug. Systemic drugs were not needed to control IOP.
Crystalline lens opacification (defined by a 2-level 
increase in lens opacity according to The Lens Opacities 
Classiﬁ  cation System III (Chylack et al 1993) appeared in 
12 eyes (55%) from 22 phakic eyes in groups 1 and 2 com-
pleting 24 month follow-up and in none of the eyes from 
the historical control group. Cataract surgery was performed 
without complications in these cases.
Floaters were described by patients in the ﬁ  rst few days 
after the injection and disappeared later in all cases. One case 
in Group 2 (case 13) suffered a central retinal vein occlusion 
at month 12. TA migrated into the anterior chamber in one 
case the day after the injection (Ruiz-Moreno et al 2005). 
There were no cases of endophthalmitis.
Discussion
PDT is known to increase local production of vascular endo-
thelial growth factor (VEGF), what might be linked with 
frequent recurrences (Wang et al 2002). Patients treated by 
PDT alone have been reported to need repeated PDT sessions 
in 90.8% of the cases at month-3 and slightly less at month-6, 
with an average 3.3 sessions in the ﬁ  rst year of therapy, and 
an average loss of 2.2 lines at month 12 (Anon 1999).
The development of new anti-VEGF drugs (Gragoudas 
et al 2004; Avery et al 2006) and the knowledge on the 
inhibitory role of steroids in the production of VEGF offer 
new approaches to the treatment of CNV.
The association of PDT and intravitreal TA to treat sub-
foveal CNV secondary to AMD has been reported by several 
groups (Jonas et al 2003; Spaide et al 2003; Augustin and 
Schmidt-Erfurth 2006b; Ruiz-Moreno et al 2006b).
A number of non-randomized studies have shown that the 
frequency of PDT sessions is reduced with combined therapy. 
Combined PDT-TA (4 mg) results in a better outcome than 
PDT alone, with reduction of the number of PDT sessions 
to 1.24 over the ﬁ  rst year and improved VA outcome by 
2.5 lines after 12 months follow-up (Chan et al 2006). The 
need to retreat was reduced to 3 of 14 eyes, with a favorable 
visual outcome in most of the treated patients (Nicolo et al 
2006). Spaide reported that the association of PDT and 4 mg 
intravitreal TA signiﬁ  cantly improved average visual acuity 
by 2.5 lines at 12-month follow-up. The rate of re-treatment 
was 1.24 for naïve eyes and 1.2 for eyes previously treated 
by PDT alone over the ﬁ  rst year (Spaide et al 2003; Spaide 
et al 2005). Rechtman has reported 21% of eyes needing PDT 
re-treatment after combined therapy with PDT and 4 mg TA, 
with a favorable visual outcome after six to twelve months 
follow-up (Rechtman et al 2004).
Our results with 19.4 ± 2.1 mg/0.1 ml TA agree with 
others injecting higher doses (25 mg/0.1 ml TA) (Augustin 
and Schmidt-Erfurth 2006a; Augustin and Schmidt-Erfurth 
2006b; Nicolo et al 2006; Ruiz-Moreno et al 2006a; Ruiz-
Moreno et al 2006b). Augustin and Schmidt-Erfurth treated 
184 eyes with AMD secondary to CNV by PDT and 25 mg 
intravitreal TA 16 hours later, and followed them for more 
than 6 months (Augustin and Schmidt-Erfurth 2006b). VA 
improvement averaged 1.22 Snellen lines after an average 
1.21 sessions of PDT. The response to the combined therapy 
was good and did not depend on the lesion composition or 
size. The same authors have reported the outcome of pure 
occult lesions in 41 eyes with the same combined therapy 
(Augustin and Schmidt-Erfurth 2006a). VA improved in 
average from 20/133 at baseline to 20/81 at two years after an 
average 1.8 PDT sessions. Nicolo et al reported 11 eyes from 
10 patients with occult CNV treated by 25 mg intravitreal 
TA followed by PDT one month later. VA improved from an 
average 20/160 to 20/80 at one year (Nicolo et al 2006).
Theoretical risks of intravitreal TA injections include 
endophthalmitis, high IOP, cataract progression, retinal 
tear, retinal detachment and ﬂ  oaters. A prolongation of 
choroidal hypoﬂ  uorescence following PDT and intravitreal 
TA has been reported recently (Luttrull and Spink 2007).
The frequency of complications associated with the use 
of high TA dose does not seem to be higher in the series 
reported (Augustin and Schmidt-Erfurth 2006a; Augustin 
and Schmidt-Erfurth 2006b; Nicolo et al 2006; Ruiz-Moreno 
et al 2006a; Ruiz-Moreno et al 2006b).
Spaide et al (Spaide et al 2003; Spaide et al 2005) 
and Rechtman et al (Rechtman et al 2004) have reported 
increased IOP in 29%–38% of eyes after 4 mg TA. Augustin 
and Schmidt-Erfurth have reported high IOP ( 25 mmHg) 
in 22 to 25% of eyes after 25 mg TA in two different clinical 
series (Augustin and Schmidt-Erfurth 2006a; Augustin and 
Schmidt-Erfurth 2006b).
Cataract progression has already been described by 
several authors. Gillies et al (2004) reported cataract surgery 
in 24% of eyes 25 months after 4 mg TA injection. Augustin 
and Schmidt-Erfurth described cataract surgery in 49% and 
42% of eyes treated by high dose intravitreal TA injection, 
respectively (Augustin and Schmidt-Erfurth 2006a; Augustin 
and Schmidt-Erfurth 2006b).
No association between increased IOP and lens opaciﬁ  ca-
tion was noticed in our series during the second year, though 
it has been described previously (Gillies et al 2004).Clinical Ophthalmology 2008:2(1) 74
Ruiz-Moreno and Montero
We have encountered no cases of endophthalmitis, retinal 
tear or retinal detachment as previously reported (Spaide 
et al 2003; Spaide et al 2005; Augustin and Schmidt-Erfurth 
2006a; Augustin and Schmidt-Erfurth 2006b; Nicolo et al 
2006). However, these series are small, and the power to 
detect these potentially severe complications is low.
The interval between PDT and TA injection is under 
discussion. We performed TA injection after PDT in order to 
avoid opaciﬁ  cation of the vitreous body by TA which might 
block laser irradiation, and the inhibition of free-radical for-
mation (Dweik et al 1997) interfering with the mechanism of 
action of PDT (Weishaupt et al 1976). The ﬁ  ve day interval 
between PDT and intravitreal TA was chosen in order to 
avoid the photosensitizing effect of verteporﬁ  n in the event 
that any problem such as retinal detachment or endophthal-
mitis might appear after the injection, and before reperfusion 
or new vessel growth might take place.
The advantages of combining high dose intravitreal TA 
to PDT are a substantial reduction in the number of PDT 
sessions and of intravitreal injections.
Increased IOP and cataracts are side effects to be consid-
ered. The advantage of using high doses of intravitreal TA 
is to achieve a longer permanence of the drug in the vitreous 
cavity instead of 3 months achieved with 4 mg intravitreal 
TA, reducing the need to repeat the injection (Tano et al 
1980). However we may also expect a longer duration of the 
side effects, especially of increased IOP. According to our 
results we can not conclude that high dose (20 mg) intravitreal 
TA is better than low dose (4 mg).
The good VA results achieved by antiangiogenic drugs 
and the low rate of adverse events have reduced the indica-
tions of PDT associated to intravitreous TA (Rosenfeld, 
Brown et al 2006). However, the use of intravitreous antian-
giogenic drugs is limited by the need of repeated intraocular 
injections and the inherent risks of endophthalmitis associ-
ated with this procedure, since antiangiogenic drugs do not 
permanently close CNV, and it is not known how early 
exudation may reappear after cessation of treatment.
The association of antiangiogenic drugs to PDT might 
be a solution to this problem. The combined treatment PDT 
and ranibizumab seems to be more effective than PDT alone 
(Heier et al 2006) and does not seem to increase adverse 
events compared with PDT alone in normal monkey eyes 
(Kim et al 2006). The association of PDT with intravitreal 
ranibizumab has been reported in the FOCUS and the 
PROTECT clinical trials (Rosenfeld, Rich et al 2006). The 
preliminary results of these trials suggest that even though 
this association is safe and may reduce the number on 
ranibizumab injections required to achieve the inactivation 
of CNV, it may also reduce the beneﬁ  ts of ranibizumab. 
A retrospective study on 24 eyes treated by PDT and intra-
vitreous bevacizumab demonstrated 2.04 Snellen lines 
mean improvement in VA (Dhalla et al 2006). Fifteen eyes 
(63%) required only a single combined treatment for CNV 
resolution and the combined therapy was followed by no 
complications, including endophthalmitis, uveitis, and ocular 
hypertension. The association of PDT and intravitreal beva-
cizumab may also be useful in treating neovascular AMD 
by reducing retreatment rates and improving visual acuity. 
However, CNV is inﬂ  uenced by several mediators, many 
of them inﬂ  ammatory, and not only by VEGF (Kijlstra et al 
2005; Tatar et al 2006). Intravitreous TA may help blocking 
these inﬂ  ammatory factors with a long standing effect due 
to its depot effect. We consider that TA associated with anti 
VEGF drugs and PDT may still have a role in the treatment 
of CNV secondary to AMD.
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